PHT-427 200mg 200mg | Purity Not Available
Adooq Bioscience
PHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
More Information Supplier PagePHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
More Information Supplier PagePHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
More Information Supplier PagePHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageLY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.
More Information Supplier PageGSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
More Information Supplier PageGSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
More Information Supplier PageGSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
More Information Supplier PageGSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
More Information Supplier Page